Oncology
For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Utilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreFor years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
It took 10 years of treatments for Anisha's IBD to enter remission. But it came back in 2019 — and just as she was about to start treatment, the pandemic hit.
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
By Natasha Steyn, Executive Director, Global Clinical Operations
By Stella Davis, Senior Manager, Regional Feasibility Network
This article is the third in a three-part series that aims to provide sponsors with information about Australia as a highly attractive option for drug research and development. Australia offers a mature infrastructure and experienced, capable local resources, especially important given global geopolitical uncertainties. Here, we examine the clinical trial start-up processes, regulatory pathway, market access, pricing system, and pricing control, with particular emphasis on cell and gene therapy with a case study to illustrate.
Interested in more? Check out part 1 and part 2.
Related Insights
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
Australia: Infrastructure and Innovations for Clinical Trials
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021